20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer to Expedite mRNA Vaccine Delivery Platform Program
November 29, 2023 03:00 ET
|
20MED Therapeutics B.V.
Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer. His appointment...
Drug Product Filled with Berkshire Sterile’s Low Loss Fill Process Receives FDA Greenlight
May 18, 2023 13:00 ET
|
Berkshire Sterile Manufacturing
Lee, MA, May 18, 2023 (GLOBE NEWSWIRE) -- RNAimmune, a biotech company focused on developing groundbreaking mRNA therapies, recently received FDA approval to begin Phase 1 clinical studies for an...
Berkshire Sterile debuts its innovative “low loss” GMP fill process
March 28, 2023 10:00 ET
|
Berkshire Sterile Manufacturing
Lee, MA, March 28, 2023 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM), a fill finish CDMO located in Lee, MA, recently completed their first GMP fill using their new low loss fill...
LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles
January 03, 2023 09:00 ET
|
leon-nanodrugs GmbH
LEON achieved superior accuracy in development of its proprietary reactor, facilitating exceptional inter-device reproducibility of particle size and distribution, and thus seamless process transfer,...
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System
November 10, 2022 08:30 ET
|
Imunon, Inc.
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA...
Harro Höfliger and LEON collaborate to bring the innovative NANOus LNP-encapsulation device to market for rapid, large-scale prophylactic vaccine manufacturing
October 26, 2022 05:00 ET
|
Leon-nanodrugs GmbH
LEON and Harro Höfliger to build and commercialize LEON’s NANOus, a novel aseptic manufacturing device to facilitate commercial production of LNP-encapsulated genetic materials and other APIsBy...
RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol
March 23, 2022 08:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward
March 07, 2022 08:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9
November 10, 2021 07:30 ET
|
Exavir Therapeutics
Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
September 16, 2021 07:30 ET
|
Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...